annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
981238288 | rs2032582 | rs2032582 | ABCB1 | CC | 4 | Efficacy | efavirenz | HIV infectious disease | Patients with the CC genotype may have increased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the AA genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the r... | https://www.clinpgx.org/clinicalAnnotation/981238288 |
981238323 | rs1695 | rs1695 | GSTP1 | AA | 3 | Efficacy | cyclophosphamide | Neoplasms | Patients with the rs1695 AA genotype and Neoplasms may have increased response to cyclophosphamide as compared to patients with GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide. | https://www.clinpgx.org/clinicalAnnotation/981238323 |
981238323 | rs1695 | rs1695 | GSTP1 | AG | 3 | Efficacy | cyclophosphamide | Neoplasms | Patients with the rs1695 AG genotype and Neoplasms may have increased response to cyclophosphamide as compared to patients with GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide. | https://www.clinpgx.org/clinicalAnnotation/981238323 |
981238323 | rs1695 | rs1695 | GSTP1 | GG | 3 | Efficacy | cyclophosphamide | Neoplasms | Patients with the rs1695 GG genotype and Neoplasms may have decreased response to cyclophosphamide as compared to patients with AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide. | https://www.clinpgx.org/clinicalAnnotation/981238323 |
981238341 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 | null | CYP2C9 | *1 | 1A | Dosage | warfarin | Cardiovascular Disease | The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors ... | https://www.clinpgx.org/clinicalAnnotation/981238341 |
981238341 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 | null | CYP2C9 | *11 | 1A | Dosage | warfarin | Cardiovascular Disease | The CYP2C9*11 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*11 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influe... | https://www.clinpgx.org/clinicalAnnotation/981238341 |
981238341 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 | null | CYP2C9 | *2 | 1A | Dosage | warfarin | Cardiovascular Disease | The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*2 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Oth... | https://www.clinpgx.org/clinicalAnnotation/981238341 |
981238341 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 | null | CYP2C9 | *3 | 1A | Dosage | warfarin | Cardiovascular Disease | The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other gene... | https://www.clinpgx.org/clinicalAnnotation/981238341 |
981238341 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 | null | CYP2C9 | *4 | 1A | Dosage | warfarin | Cardiovascular Disease | The CYP2C9*4 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*4 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influenc... | https://www.clinpgx.org/clinicalAnnotation/981238341 |
981238341 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 | null | CYP2C9 | *5 | 1A | Dosage | warfarin | Cardiovascular Disease | The CYP2C9*5 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*5 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influenc... | https://www.clinpgx.org/clinicalAnnotation/981238341 |
981238341 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 | null | CYP2C9 | *6 | 1A | Dosage | warfarin | Cardiovascular Disease | The CYP2C9*6 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*6 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfa... | https://www.clinpgx.org/clinicalAnnotation/981238341 |
981238341 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 | null | CYP2C9 | *8 | 1A | Dosage | warfarin | Cardiovascular Disease | The CYP2C9*8 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C9*8 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influenc... | https://www.clinpgx.org/clinicalAnnotation/981238341 |
981238370 | rs1979277 | rs1979277 | SHMT1 | AA | 3 | Toxicity | methotrexate | Acute lymphoblastic leukemia | Pediatric patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased catalytic activity of TYMS as compared to pediatric patients with the AG and GG genotype. Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymp... | https://www.clinpgx.org/clinicalAnnotation/981238370 |
981238370 | rs1979277 | rs1979277 | SHMT1 | AG | 3 | Toxicity | methotrexate | Acute lymphoblastic leukemia | Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma wh... | https://www.clinpgx.org/clinicalAnnotation/981238370 |
981238370 | rs1979277 | rs1979277 | SHMT1 | GG | 3 | Toxicity | methotrexate | Acute lymphoblastic leukemia | Pediatric patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma wh... | https://www.clinpgx.org/clinicalAnnotation/981238370 |
981238397 | rs1695 | rs1695 | GSTP1 | AA | 3 | Toxicity | mercaptopurine;methotrexate | Acute lymphoblastic leukemia;Drug Toxicity | Patients with acute lymphoblastic leukemia (ALL) and the rs1695 AA genotype may be less likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with m... | https://www.clinpgx.org/clinicalAnnotation/981238397 |
981238397 | rs1695 | rs1695 | GSTP1 | AG | 3 | Toxicity | mercaptopurine;methotrexate | Acute lymphoblastic leukemia;Drug Toxicity | Patients with acute lymphoblastic leukemia (ALL) and the rs1695 AG genotype may be less likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with m... | https://www.clinpgx.org/clinicalAnnotation/981238397 |
981238397 | rs1695 | rs1695 | GSTP1 | GG | 3 | Toxicity | mercaptopurine;methotrexate | Acute lymphoblastic leukemia;Drug Toxicity | Patients with acute lymphoblastic leukemia (ALL) and the rs1695 GG genotype may be more likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated... | https://www.clinpgx.org/clinicalAnnotation/981238397 |
981238415 | rs1127354 | rs1127354 | ITPA | AA | 3 | Efficacy;Toxicity | methotrexate | Acute lymphoblastic leukemia;Rheumatoid arthritis | Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that... | https://www.clinpgx.org/clinicalAnnotation/981238415 |
981238415 | rs1127354 | rs1127354 | ITPA | AC | 3 | Efficacy;Toxicity | methotrexate | Acute lymphoblastic leukemia;Rheumatoid arthritis | Patients with the AC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that... | https://www.clinpgx.org/clinicalAnnotation/981238415 |
981238415 | rs1127354 | rs1127354 | ITPA | CC | 3 | Efficacy;Toxicity | methotrexate | Acute lymphoblastic leukemia;Rheumatoid arthritis | Patients with the CC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) a decreased, but not absent, risk for gastrointestinal toxicities 2) an increased response to folic acid and methotrexate as compared to patients with the AA and AC genotype. However, this association is contradict... | https://www.clinpgx.org/clinicalAnnotation/981238415 |
981238437 | rs1057910 | rs1057910 | CYP2C9 | AA | 3 | Toxicity | Antiinflammatory agents, non-steroids;celecoxib;diclofenac | null | Patients with the AA genotype who are treated with non-steroid antiinflammatory agents, celecoxib or diclofenac may have a decreased, but not absent, risk of gastrointestinal bleeding as compared to patients with the AC and CC genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was d... | https://www.clinpgx.org/clinicalAnnotation/981238437 |
981238437 | rs1057910 | rs1057910 | CYP2C9 | AC | 3 | Toxicity | Antiinflammatory agents, non-steroids;celecoxib;diclofenac | null | Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not cl... | https://www.clinpgx.org/clinicalAnnotation/981238437 |
981238437 | rs1057910 | rs1057910 | CYP2C9 | CC | 3 | Toxicity | Antiinflammatory agents, non-steroids;celecoxib;diclofenac | null | Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not cl... | https://www.clinpgx.org/clinicalAnnotation/981238437 |
981238459 | rs1057910 | rs1057910 | CYP2C9 | AA | 3 | Efficacy | losartan | null | Subjects with the AA genotype who are treated with losartan may have increased metabolism of losartan as compared to subjects with the CA and CC genotype. Other genetic and clinical factors may also influence metabolism of losartan. | https://www.clinpgx.org/clinicalAnnotation/981238459 |
981238459 | rs1057910 | rs1057910 | CYP2C9 | AC | 3 | Efficacy | losartan | null | Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan. | https://www.clinpgx.org/clinicalAnnotation/981238459 |
981238459 | rs1057910 | rs1057910 | CYP2C9 | CC | 3 | Efficacy | losartan | null | Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan. | https://www.clinpgx.org/clinicalAnnotation/981238459 |
981238501 | CYP2C9*1, CYP2C9*2, CYP2C9*3 | null | CYP2C9 | *1 | 1A | Toxicity | phenytoin | Epilepsy | The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a decreased, but not absent, risk of drug toxicity when treated with phenytoin as compared to patients with a no function allele in combination with a no... | https://www.clinpgx.org/clinicalAnnotation/981238501 |
981238501 | CYP2C9*1, CYP2C9*2, CYP2C9*3 | null | CYP2C9 | *2 | 1A | Toxicity | phenytoin | Epilepsy | The CYP2C9*2 allele is assigned as a decreased function allele by CPIC. Patients carrying the *2 in combination with a normal function allele may have a may have a similar risk of drug toxicity when treated with phenytoin as compared to patients carrying two normal function alleles, while patients carrying the *2 allel... | https://www.clinpgx.org/clinicalAnnotation/981238501 |
981238501 | CYP2C9*1, CYP2C9*2, CYP2C9*3 | null | CYP2C9 | *3 | 1A | Toxicity | phenytoin | Epilepsy | The CYP2C9*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have an increased risk of drug toxicity when treated when phenytoin as compared to patients with two normal function alleles. However, conflicting evid... | https://www.clinpgx.org/clinicalAnnotation/981238501 |
981238550 | rs1051740 | rs1051740 | EPHX1 | CC | 3 | Metabolism/PK | carbamazepine | Epilepsy | Patients with the CC genotype and Epilepsy may have increased metabolism of carbamazepine as compared to patients with the the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and cli... | https://www.clinpgx.org/clinicalAnnotation/981238550 |
981238550 | rs1051740 | rs1051740 | EPHX1 | CT | 3 | Metabolism/PK | carbamazepine | Epilepsy | Patients with the CT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC genotype, or an increased metabolism as compared to patients with the the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and do... | https://www.clinpgx.org/clinicalAnnotation/981238550 |
981238550 | rs1051740 | rs1051740 | EPHX1 | TT | 3 | Metabolism/PK | carbamazepine | Epilepsy | Patients with the TT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and cli... | https://www.clinpgx.org/clinicalAnnotation/981238550 |
981238562 | rs1051266 | rs1051266 | SLC19A1 | CC | 4 | Metabolism/PK | methotrexate | Acute lymphoblastic leukemia;Burkitt Lymphoma;Leukemia;Lymphoma, T-Cell;Neoplasms;Osteosarcoma | The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and d... | https://www.clinpgx.org/clinicalAnnotation/981238562 |
981238562 | rs1051266 | rs1051266 | SLC19A1 | CT | 4 | Metabolism/PK | methotrexate | Acute lymphoblastic leukemia;Burkitt Lymphoma;Leukemia;Lymphoma, T-Cell;Neoplasms;Osteosarcoma | The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and d... | https://www.clinpgx.org/clinicalAnnotation/981238562 |
981238562 | rs1051266 | rs1051266 | SLC19A1 | TT | 4 | Metabolism/PK | methotrexate | Acute lymphoblastic leukemia;Burkitt Lymphoma;Leukemia;Lymphoma, T-Cell;Neoplasms;Osteosarcoma | The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and d... | https://www.clinpgx.org/clinicalAnnotation/981238562 |
981238570 | rs1050828 | rs1050828 | G6PD;IKBKG | CC | 3 | Toxicity | artesunate;primaquine;pyrimethamine;sulfadoxine | null | Pediatric patients with the CC genotype may have decreased, but not absent, risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to ... | https://www.clinpgx.org/clinicalAnnotation/981238570 |
981238570 | rs1050828 | rs1050828 | G6PD;IKBKG | CT | 3 | Toxicity | artesunate;primaquine;pyrimethamine;sulfadoxine | null | Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquin... | https://www.clinpgx.org/clinicalAnnotation/981238570 |
981238570 | rs1050828 | rs1050828 | G6PD;IKBKG | TT | 3 | Toxicity | artesunate;primaquine;pyrimethamine;sulfadoxine | null | Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquin... | https://www.clinpgx.org/clinicalAnnotation/981238570 |
981238910 | rs5219 | rs5219 | KCNJ11 | CC | 3 | Efficacy | metformin;sulfonamides, urea derivatives | Diabetes Mellitus, Type 2 | Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, ur... | https://www.clinpgx.org/clinicalAnnotation/981238910 |
981238910 | rs5219 | rs5219 | KCNJ11 | CT | 3 | Efficacy | metformin;sulfonamides, urea derivatives | Diabetes Mellitus, Type 2 | Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. Thi... | https://www.clinpgx.org/clinicalAnnotation/981238910 |
981238910 | rs5219 | rs5219 | KCNJ11 | TT | 3 | Efficacy | metformin;sulfonamides, urea derivatives | Diabetes Mellitus, Type 2 | Patients with the TT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, u... | https://www.clinpgx.org/clinicalAnnotation/981238910 |
981239532 | rs104894539 | rs104894539 | VKORC1 | AA | 3 | Dosage | warfarin | null | Patients with the AA genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239532 |
981239532 | rs104894539 | rs104894539 | VKORC1 | AC | 3 | Dosage | warfarin | null | Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239532 |
981239532 | rs104894539 | rs104894539 | VKORC1 | CC | 3 | Dosage | warfarin | null | Patients with the CC genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239532 |
981239544 | rs104894540 | rs104894540 | VKORC1 | AA | 3 | Dosage | warfarin | null | Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239544 |
981239544 | rs104894540 | rs104894540 | VKORC1 | AG | 3 | Dosage | warfarin | null | Patients with the AG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239544 |
981239544 | rs104894540 | rs104894540 | VKORC1 | GG | 3 | Dosage | warfarin | null | Patients with the GG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239544 |
981239556 | rs104894541 | rs104894541 | VKORC1 | CC | 3 | Dosage | warfarin | null | Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239556 |
981239556 | rs104894541 | rs104894541 | VKORC1 | CT | 3 | Dosage | warfarin | null | Patients with the CT genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239556 |
981239556 | rs104894541 | rs104894541 | VKORC1 | TT | 3 | Dosage | warfarin | null | Patients with the TT genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239556 |
981239568 | rs104894542 | rs104894542 | VKORC1 | AA | 3 | Dosage | warfarin | null | Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239568 |
981239568 | rs104894542 | rs104894542 | VKORC1 | AC | 3 | Dosage | warfarin | null | Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239568 |
981239568 | rs104894542 | rs104894542 | VKORC1 | CC | 3 | Dosage | warfarin | null | Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose. | https://www.clinpgx.org/clinicalAnnotation/981239568 |
981239773 | rs8099917 | rs8099917 | IFNL3 | GG | 1B | Efficacy | interferons;peginterferon alfa-2a;peginterferon alfa-2b;ribavirin | Chronic hepatitis C virus infection | Patients with the rs8099917 GG genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to p... | https://www.clinpgx.org/clinicalAnnotation/981239773 |
981239773 | rs8099917 | rs8099917 | IFNL3 | GT | 1B | Efficacy | interferons;peginterferon alfa-2a;peginterferon alfa-2b;ribavirin | Chronic hepatitis C virus infection | Patients with the rs8099917 GT genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to p... | https://www.clinpgx.org/clinicalAnnotation/981239773 |
981239773 | rs8099917 | rs8099917 | IFNL3 | TT | 1B | Efficacy | interferons;peginterferon alfa-2a;peginterferon alfa-2b;ribavirin | Chronic hepatitis C virus infection | Patients with the rs8099917 TT genotype and chronic hepatitis C infection may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence respon... | https://www.clinpgx.org/clinicalAnnotation/981239773 |
981240029 | rs5219 | rs5219 | KCNJ11 | CC | 3 | Efficacy | sulfonamides, urea derivatives | Diabetes Mellitus, Type 2 | Patients with CC genotype and Type 2 diabetes may have a poorer response (smaller decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas. | https://www.clinpgx.org/clinicalAnnotation/981240029 |
981240029 | rs5219 | rs5219 | KCNJ11 | CT | 3 | Efficacy | sulfonamides, urea derivatives | Diabetes Mellitus, Type 2 | Patients with CT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC, or a poorer response (smaller decrease in HbA1c) as compared to patients with genotype TT. Other genetic or clinical factors may also in... | https://www.clinpgx.org/clinicalAnnotation/981240029 |
981240029 | rs5219 | rs5219 | KCNJ11 | TT | 3 | Efficacy | sulfonamides, urea derivatives | Diabetes Mellitus, Type 2 | Patients with TT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas. | https://www.clinpgx.org/clinicalAnnotation/981240029 |
981344897 | rs4149056 | rs4149056 | SLCO1B1 | CC | 3 | Toxicity | cerivastatin | Rhabdomyolysis | Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related ... | https://www.clinpgx.org/clinicalAnnotation/981344897 |
981344897 | rs4149056 | rs4149056 | SLCO1B1 | CT | 3 | Toxicity | cerivastatin | Rhabdomyolysis | Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdo... | https://www.clinpgx.org/clinicalAnnotation/981344897 |
981344897 | rs4149056 | rs4149056 | SLCO1B1 | TT | 3 | Toxicity | cerivastatin | Rhabdomyolysis | Patients with the TT genotype may have a lower risk of cerivastatin-related rhabdomyolysis as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related r... | https://www.clinpgx.org/clinicalAnnotation/981344897 |
981345277 | rs25487 | rs25487 | XRCC1 | CC | 3 | Efficacy | fluorouracil | Colonic Neoplasms;Colorectal Neoplasms;Neoplasms;Rectal Neoplasms;Uterine Cervical Neoplasm | Patients with the CC genotype and cancer may have increased response to fluorouracil-containing chemotherapy regimens, as well as a decreased risk for and a later onset of sensory neuropathy, as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drug... | https://www.clinpgx.org/clinicalAnnotation/981345277 |
981345277 | rs25487 | rs25487 | XRCC1 | CT | 3 | Efficacy | fluorouracil | Colonic Neoplasms;Colorectal Neoplasms;Neoplasms;Rectal Neoplasms;Uterine Cervical Neoplasm | Patients with the CT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs ... | https://www.clinpgx.org/clinicalAnnotation/981345277 |
981345277 | rs25487 | rs25487 | XRCC1 | TT | 3 | Efficacy | fluorouracil | Colonic Neoplasms;Colorectal Neoplasms;Neoplasms;Rectal Neoplasms;Uterine Cervical Neoplasm | Patients with the TT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs ... | https://www.clinpgx.org/clinicalAnnotation/981345277 |
981345285 | rs25487 | rs25487 | XRCC1 | CC | 4 | Efficacy;Toxicity | cyclophosphamide | Neoplasms;Ovarian Neoplasms | Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this varian... | https://www.clinpgx.org/clinicalAnnotation/981345285 |
981345285 | rs25487 | rs25487 | XRCC1 | CT | 4 | Efficacy;Toxicity | cyclophosphamide | Neoplasms;Ovarian Neoplasms | Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Oth... | https://www.clinpgx.org/clinicalAnnotation/981345285 |
981345285 | rs25487 | rs25487 | XRCC1 | TT | 4 | Efficacy;Toxicity | cyclophosphamide | Neoplasms;Ovarian Neoplasms | Patients with the TT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Oth... | https://www.clinpgx.org/clinicalAnnotation/981345285 |
981345293 | rs4149056 | rs4149056 | SLCO1B1 | CC | 1A | Metabolism/PK | pravastatin | null | Patients with the rs4149056 CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the phar... | https://www.clinpgx.org/clinicalAnnotation/981345293 |
981345293 | rs4149056 | rs4149056 | SLCO1B1 | CT | 1A | Metabolism/PK | pravastatin | null | Patients with the rs4149056 CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the phar... | https://www.clinpgx.org/clinicalAnnotation/981345293 |
981345293 | rs4149056 | rs4149056 | SLCO1B1 | TT | 1A | Metabolism/PK | pravastatin | null | Patients with the rs4149056 TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers th... | https://www.clinpgx.org/clinicalAnnotation/981345293 |
981345311 | rs4149056 | rs4149056 | SLCO1B1 | CC | 3 | Metabolism/PK | atorvastatin;rifampin | null | Patients with the CC genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/981345311 |
981345311 | rs4149056 | rs4149056 | SLCO1B1 | CT | 3 | Metabolism/PK | atorvastatin;rifampin | null | Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/981345311 |
981345311 | rs4149056 | rs4149056 | SLCO1B1 | TT | 3 | Metabolism/PK | atorvastatin;rifampin | null | Patients with the TT genotype may have increased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/981345311 |
981345350 | rs4149056 | rs4149056 | SLCO1B1 | CC | 1A | Metabolism/PK | rosuvastatin | Hypercholesterolemia | Patients with the rs4149056 CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin an... | https://www.clinpgx.org/clinicalAnnotation/981345350 |
981345350 | rs4149056 | rs4149056 | SLCO1B1 | CT | 1A | Metabolism/PK | rosuvastatin | Hypercholesterolemia | Patients with the rs4149056 CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin an... | https://www.clinpgx.org/clinicalAnnotation/981345350 |
981345350 | rs4149056 | rs4149056 | SLCO1B1 | TT | 1A | Metabolism/PK | rosuvastatin | Hypercholesterolemia | Patients with the rs4149056 TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and... | https://www.clinpgx.org/clinicalAnnotation/981345350 |
981345382 | rs4149056 | rs4149056 | SLCO1B1 | CC | 2A | Toxicity | HMG-CoA reductase inhibitors | statin-related myopathy | Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy. | https://www.clinpgx.org/clinicalAnnotation/981345382 |
981345382 | rs4149056 | rs4149056 | SLCO1B1 | CT | 2A | Toxicity | HMG-CoA reductase inhibitors | statin-related myopathy | Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy. | https://www.clinpgx.org/clinicalAnnotation/981345382 |
981345382 | rs4149056 | rs4149056 | SLCO1B1 | TT | 2A | Toxicity | HMG-CoA reductase inhibitors | statin-related myopathy | Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with statins as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy. | https://www.clinpgx.org/clinicalAnnotation/981345382 |
981352141 | rs1050828 | rs1050828 | G6PD | CC | 4 | Toxicity | artesunate;chlorproguanil;dapsone | Malaria | Patients with the CC genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have a decreased, but not absent, risk of hemolysis and severe/unsafe hemoglobin decreases as compared to patients with the CT or TT genotypes. However, one study failed to find this association. Other genetic and... | https://www.clinpgx.org/clinicalAnnotation/981352141 |
981352141 | rs1050828 | rs1050828 | G6PD | CT | 4 | Toxicity | artesunate;chlorproguanil;dapsone | Malaria | Patients with the CT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of hemolysis and severe/unsafe hemoglobin decreases as compared to patients with the CC genotype. However, one study failed to find this association. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/981352141 |
981352141 | rs1050828 | rs1050828 | G6PD | TT | 4 | Toxicity | artesunate;chlorproguanil;dapsone | Malaria | Patients with the TT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of hemolysis and severe/unsafe hemoglobin decreases as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, ch... | https://www.clinpgx.org/clinicalAnnotation/981352141 |
981419257 | HLA-B*57:01 | null | HLA-B | *57:01 | 1A | Toxicity | abacavir | Drug Hypersensitivity;HIV infectious disease | Patients with one or two copies of the HLA-B*57:01 allele have an increased risk of hypersensitivity to abacavir as compared to patients with no HLA-B*57:01 alleles or negative for the HLA-B*57:01 test. Other genetic and clinical factors may also influence the risk of abacavir-induced adverse reactions. | https://www.clinpgx.org/clinicalAnnotation/981419257 |
981419260 | HLA-B*58:01 | null | HLA-B | *58:01 | 1A | Toxicity | allopurinol | Drug Hypersensitivity;Drug Reaction with Eosinophilia and Systemic Symptoms;Severe Cutaneous Adverse Reactions;Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis | Patients with one or two copies of the HLA-B*58:01 allele may have an increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with allopurinol as compared to patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test. However, co... | https://www.clinpgx.org/clinicalAnnotation/981419260 |
981419263 | HLA-B*15:02, HLA-B*15:11 | null | HLA-B | *15:02 | 1A | Toxicity | carbamazepine | Drug Reaction with Eosinophilia and Systemic Symptoms;Maculopapular Exanthema;Severe Cutaneous Adverse Reactions;Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis | Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk of Severe Cutaneous Adverse Reactions when treated with carbamazepine as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. However, conflicting evidence has been reported. Other genetic and clinical... | https://www.clinpgx.org/clinicalAnnotation/981419263 |
981419263 | HLA-B*15:02, HLA-B*15:11 | null | HLA-B | *15:11 | 1A | Toxicity | carbamazepine | Drug Reaction with Eosinophilia and Systemic Symptoms;Maculopapular Exanthema;Severe Cutaneous Adverse Reactions;Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis | Patients with one or two copies of the HLA-B*15:11 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with carbamazepine as compared to patients with no HLA-B*15:11 alleles or negative for the HLA-B*15:11 test. However, ... | https://www.clinpgx.org/clinicalAnnotation/981419263 |
981419266 | HLA-B*15:02 | null | HLA-B | *15:02 | 1A | Toxicity | phenytoin | Drug Reaction with Eosinophilia and Systemic Symptoms;Severe Cutaneous Adverse Reactions;Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis | Patients with one or two copies of the HLA-B*15:02 allele may have an increased risk of Severe Cutaneous Adverse Reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, when treated with phenytoin as compared to patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test. However, conf... | https://www.clinpgx.org/clinicalAnnotation/981419266 |
981419487 | rs118192172 | rs118192172 | RYR1 | CC | 3 | Toxicity | HMG-CoA reductase inhibitors | Muscular Diseases | Patients with the rs118192172 CC genotype may have decreased risk to statin-related myopathy as compared patients with the TT or CT genotype. Other genetic and clinical factors may also influence risk of toxicity to statins. | https://www.clinpgx.org/clinicalAnnotation/981419487 |
981419487 | rs118192172 | rs118192172 | RYR1 | CT | 3 | Toxicity | HMG-CoA reductase inhibitors | Muscular Diseases | Patients with the rs118192172 CT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to statins. | https://www.clinpgx.org/clinicalAnnotation/981419487 |
981419487 | rs118192172 | rs118192172 | RYR1 | TT | 3 | Toxicity | HMG-CoA reductase inhibitors | Muscular Diseases | Patients with the rs118192172 TT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to statins. | https://www.clinpgx.org/clinicalAnnotation/981419487 |
981419532 | rs4693075 | rs4693075 | COQ2 | CC | 3 | Toxicity | atorvastatin;HMG-CoA reductase inhibitors;rosuvastatin | Muscular Diseases | Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient's risk of toxicity. | https://www.clinpgx.org/clinicalAnnotation/981419532 |
981419532 | rs4693075 | rs4693075 | COQ2 | CG | 3 | Toxicity | atorvastatin;HMG-CoA reductase inhibitors;rosuvastatin | Muscular Diseases | Patients with the CG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity. | https://www.clinpgx.org/clinicalAnnotation/981419532 |
981419532 | rs4693075 | rs4693075 | COQ2 | GG | 3 | Toxicity | atorvastatin;HMG-CoA reductase inhibitors;rosuvastatin | Muscular Diseases | Patients with the GG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity. | https://www.clinpgx.org/clinicalAnnotation/981419532 |
981419540 | rs6535454 | rs6535454 | COQ2 | AA | 3 | Toxicity | atorvastatin;HMG-CoA reductase inhibitors;rosuvastatin | Muscular Diseases | Patients with the AA genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin. | https://www.clinpgx.org/clinicalAnnotation/981419540 |
981419540 | rs6535454 | rs6535454 | COQ2 | AG | 3 | Toxicity | atorvastatin;HMG-CoA reductase inhibitors;rosuvastatin | Muscular Diseases | Patients with the AG genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin. | https://www.clinpgx.org/clinicalAnnotation/981419540 |
981419540 | rs6535454 | rs6535454 | COQ2 | GG | 3 | Toxicity | atorvastatin;HMG-CoA reductase inhibitors;rosuvastatin | Muscular Diseases | Patients with the GG genotype may have decreased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk to statin. | https://www.clinpgx.org/clinicalAnnotation/981419540 |
981419550 | rs2819742 | rs2819742 | RYR2 | AA | 3 | Toxicity | cerivastatin | Rhabdomyolysis | Patients with the AA genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. | https://www.clinpgx.org/clinicalAnnotation/981419550 |
981419550 | rs2819742 | rs2819742 | RYR2 | AG | 3 | Toxicity | cerivastatin | Rhabdomyolysis | Patients with the AG genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. | https://www.clinpgx.org/clinicalAnnotation/981419550 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.